Since we and others have shown that the roles of the Hippo pathway components are cell-type dependent, it is likely that the lack of enhancement of cardiac hypertrophy in Lats2 +/- mice in response to TAC is attributable to the effect of Lats2 downregulation in non-myocytes. The gene discussed is LATS2; the disease is cardiac hypertrophy.